bioAffinity Technologies, Inc. (BIAF): Entry into a Material Definitive Agreement
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 5 ex10-1.htm EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT THIS SECURITIES PURCHASE AGREEMENT (this “ Agreement ”) is entered into and made effective as of June 16, 2026, by and between BIOAFFINITY TECHNOLOGIES, INC., a Delaware corporation (the “ Company ”), and eac
How this was made
The 30-second read
Why it matters
This is a primary-source disclosure of a financing agreement, which can change dilution expectations and perceived funding runway. However, the excerpt does not include the economic terms needed to quantify impact.
Market read
Material definitive agreement disclosure can drive immediate repricing, but the excerpt lacks proceeds and security economics, limiting conviction on direction.
What to watch
Traders should focus on the security type (common vs preferred vs warrants), any conversion/discount mechanics, aggregate proceeds, and closing timing/conditions—none of which are visible in the provided excerpt.
Background
The company filed an SEC Form 8-K for Item 1.01, indicating it entered a material definitive agreement: a securities purchase agreement effective June 16, 2026.
Ticker impact
bioAffinity Technologies entered a material definitive securities purchase agreement effective June 16, 2026, disclosed via an SEC 8-K.
Near-term volatility possible around deal terms once the full purchase price, security type, and closing conditions are known; direction depends on dilution size and investor appetite.
The 8-K confirms entry into a material definitive agreement, but the provided excerpt is largely boilerplate definitions and does not include the key economic terms (e.g., gross proceeds, security mix, conversion/discounts).
Market effects
Adds incremental financing activity signal for small-cap biotech/life-sciences issuers, but no sector-wide read-across is provided in the excerpt.
No specific regional market linkage mentioned.
No global macro or cross-border transaction details provided in the excerpt.
Counterpoint
If the agreement is non-dilutive or structured with limited dilution (e.g., warrants with low exercise pressure), the market may over-discount the risk and the stock could stabilize once terms are read.
Key entities
- CompanybioAffinity Technologies, Inc.
Subject of the 8-K; entered into a securities purchase agreement effective June 16, 2026.
- CounterpartiesPurchasers (unnamed in excerpt)
Investors identified on the agreement signature pages; specific identities and terms are not shown in the excerpt.
